Skip to main content
SpringerLink
Log in

Drosophila as a Tool for Investigating the Molecular Genetics of Insecticide Resistance

  • Chapter
Molecular Approaches to Fundamental and Applied Entomology

Part of the book series: Springer Series in Experimental Entomology ((SSEXP))

Abstract

Molecular studies on insecticide resistance are important for both fundamental and applied research. Resistance has developed so rapidly that we can gather meaningful data on selective changes during evolution (Kimura 1968; Roush and McKenzie 1987). Elucidation of the molecular mechanisms involved may allow for a clearer understanding of the modes of action of insecticides and the pathways for their degradation. Such knowledge could facilitate the rational design of novel insecticidal compounds and help in the formulation of pest control strategies for the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ahmad M, Gladwell RT, McCaffery AR (1989) Decreased nerve sensitivity is a mechanism of resistance in a pyrethriodresistant strain of Heliothis armigerafrom Thailand. Pestic Biochem Physiol 35:165–171

    CAS  Google Scholar 

  • Arpagaus M, Toutant J-P Alterations in the mucosal immune system in ulcerative colitis and Crohn’s disease. Med Clin North Am 1990;78:1207–1231.

    Google Scholar 

  • Ashburner M. Maintenance therapy in ulcerative colitis and Crohn’s disease. J Clin Gastroenterol 1995;20:117–122.

    Google Scholar 

  • Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993;342:412–417.

    PubMed  CAS  Google Scholar 

  • Hanauer SB. Medical therapy in ulcerative colitis. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease. 4th ed. Baltimore: Williams & Wilkins, 1995:664–694.

    Google Scholar 

  • Meyers S, Sachar DB. Medical therapy of Crohn’s disease. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease. 4th ed. Baltimore: Williams & Wilkins; 1995:695–714.

    Google Scholar 

  • Stark ME, Tremaine WJ. Maintenance of symptomatic remission in patients with Crohn’s disease. Mayo Clin Proc 1993;68:1183–1190.

    PubMed  CAS  Google Scholar 

  • Svarts N. Sulfasalazine. II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 1988;83:497–503.

    Google Scholar 

  • Greenfield SM, Punchard NA, Teare JP, et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Therapy 1993;7:369–383.

    CAS  Google Scholar 

  • Hanauer SB, Meyers S, Sachar DB. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease. 4th ed. Baltimore: Williams & Wilkins, 1995:643–663.

    Google Scholar 

  • Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N Engl J Med 1980;303:1499–1502.

    PubMed  CAS  Google Scholar 

  • Eliakim R, Rachmilewitz D. Potential mediators on inflammatory bowel disease. Gastroenterol Intl 1992;5:48–56.

    Google Scholar 

  • Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859–861.

    PubMed  CAS  Google Scholar 

  • Lauritsen K, Laursen S, Bukhave K, et al. Inflammatory intermediaries in inflammatory bowel disease. Int J Colorectal Dis 1989;4:75–90.

    PubMed  CAS  Google Scholar 

  • Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-Aminosalicylic acid in the treatment of ulcerative colitis. Ann Int Med 1993;118:540–549.

    PubMed  CAS  Google Scholar 

  • Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance treatment of Crohn’s disease: a meta analysis. Am J Gastroenterol 1994;84:2116–2124.

    Google Scholar 

  • Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–266.

    PubMed  CAS  Google Scholar 

  • Margolin ML, Krumholz MP, Fochios SE, et al. Clinical trials in ulcerative colitis: II. Historical review. Am J Gastroenterol 1988;83:227–243.

    PubMed  CAS  Google Scholar 

  • Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety 1991;6:192–219.

    PubMed  CAS  Google Scholar 

  • Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study (NCCDS): results of drug treatment. Gastroenterology 1979;77:847–869.

    PubMed  CAS  Google Scholar 

  • Saloman P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn’s disease? A meta-analysis. J Clin Gastroenterol 1992;14:211–215.

    Google Scholar 

  • Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491.

    PubMed  CAS  Google Scholar 

  • Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983;28:833.

    PubMed  CAS  Google Scholar 

  • Thomson ABR. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1991;5:449.

    PubMed  CAS  Google Scholar 

  • Marshall JK, Irvine EJ. Topical aminosalicylate (ASA) therapy for distal ulcerative colitis: a meta-analysis. Gastroenterology 1994;106:A1037.

    Google Scholar 

  • Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for the treatment of active ulcerative colitis. Results of a controlled trial. Am J Gastroenterol 1993;88:1188–1197.

    PubMed  CAS  Google Scholar 

  • Wadworth AN, Ritton A. Olsalazine. A review of its pharmicokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 1991;41:647–664.

    PubMed  CAS  Google Scholar 

  • Hanauer SB, Baert F. Medical therapy of inflammatory bowel disease. Med Clin North Am 1994;78:1413–1426.

    PubMed  CAS  Google Scholar 

  • Singleton JW, Hanauer SB, Gitnick GL, et al, and the Pentasa Crohn’s disease study group. Mesalamine capsules for the treatment of active Crohn’s disease. Results of a 16 week trial. Gastroenterology 1993;104:1293–1301.

    PubMed  CAS  Google Scholar 

  • Messori A, Brignila C, Trallori G, et al. Effectiveness of 5-Aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994;89:692–698.

    PubMed  CAS  Google Scholar 

  • Hanauer SB. Drug therapy: inflammatory bowel disease. N Engl J Med 1996;334:841–848.

    PubMed  CAS  Google Scholar 

  • Cohen RD, Hanauer SB. Immunomodulatory agents and other medical therapies in inflammatory bowel disease. Curr Opin Gastroenterol 1995;11:321–330.

    CAS  Google Scholar 

  • Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease: a review of their mechanisms of efficacy and place in therapy. Drugs 1989;38:267–288.

    PubMed  CAS  Google Scholar 

  • Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4:407–414.

    Google Scholar 

  • Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Int Med 1993;119:1198–1208.

    PubMed  CAS  Google Scholar 

  • Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. British Med J 1955;2:1041–1048.

    CAS  Google Scholar 

  • Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin versus hydrocortisone in intravenous treatment of ulcerative colitis. Gastroenterology 1983;85:351–357.

    PubMed  CAS  Google Scholar 

  • Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J 1962;2:441–443.

    PubMed  CAS  Google Scholar 

  • Lennard-Jones JE. Toward optimal use of corticosteroids in ulcerative colitis and Crohn’s disease. Gut 1983;24:177.

    PubMed  CAS  Google Scholar 

  • Meyers S, Janowitz HD. Systemic corticosteroid therapy of ulcerative colitis. Gastroenterology 1985;89:1189–1199.

    PubMed  CAS  Google Scholar 

  • Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Amer 1990;74:119–131.

    CAS  Google Scholar 

  • Mulder CJ, Tygat GN. Review article: topical corticosteroids in inflammatory bowel disease. Aliment Pharmacol Ther 1993;7:125–130.

    PubMed  CAS  Google Scholar 

  • Danielsson A, Lofberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992;27:9–12.

    PubMed  CAS  Google Scholar 

  • Shepard HA, Barr GD, Jewel DP. Use of an iv steroid regimen in the treatment of acute Crohn’s disease. J Clin Gastroenterol 1986;8(2):154–159.

    Google Scholar 

  • Bjarnason I, Hayllar J, MacPherson A, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832–1847.

    PubMed  CAS  Google Scholar 

  • Bianchi Porro G, Prantera C, Campieri M, et al. Comparative trial of budesonide and methylpred-nisolone enemas in active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994;6:125–130.

    Google Scholar 

  • Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as a positive control. Scand J Gastroenterol 1991;26:1225–1230.

    Google Scholar 

  • Danielsson A, Hellers G, Lyrenas E, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987;22:987.

    PubMed  CAS  Google Scholar 

  • Rutgeerts, P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–845.

    PubMed  CAS  Google Scholar 

  • Greenberg GR, Feagan GB, et al, and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn’s disease. N Engl J Med 1994;331:836–841.

    PubMed  CAS  Google Scholar 

  • Sachar DB. Budesonise for inflammatory bowel disease. Is it the magic bullet? N Engl J Med 1994;331:873–874.

    PubMed  CAS  Google Scholar 

  • Greenberg GR, Feagan BG, et al. Oral Budesonide as Maintenance Treatment for Crohn’s Disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996;110:299.

    Google Scholar 

  • Adler DJ, Korelitz BI. The therapeutic efficacy of 6-Mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:712–722.

    Google Scholar 

  • Choi PM, Targan SR. Immunomodualatory treatment in inflammatory bowel disease. Dig Dis Sci 1994;39:1885–1892.

    PubMed  CAS  Google Scholar 

  • Gearge J, Pou R, Bodain C, et al. 6-Mercaptopurine is effective in chronic ulcerative colitis but how long do you use it? Gastroenterology 1994;106:A686.

    Google Scholar 

  • Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-MP in Crohn’s disease. A meta-analysis. Ann Int Med 1995;122:132–142.

    Google Scholar 

  • Ewe K, Press AG, Singe C, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993;105:367–372.

    PubMed  CAS  Google Scholar 

  • Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term randomised, double-blind study. N Engl J Med 1981;302:981–987.

    Google Scholar 

  • Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short and long term toxicity. Ann Intern Med 1989;111:641–649.

    PubMed  CAS  Google Scholar 

  • Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249–1252.

    PubMed  CAS  Google Scholar 

  • Haber DJ, Meltzer SJ, Present DH, et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91:982–986.

    PubMed  CAS  Google Scholar 

  • Connell WR, Kamm, MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081–1085.

    PubMed  CAS  Google Scholar 

  • Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc 1992;67:981–990.

    PubMed  CAS  Google Scholar 

  • Lichteger S, Present DH, Kornbluth A, et al. Cyclopsorin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–1845.

    Google Scholar 

  • Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Dis 1995;l:48–63.

    Google Scholar 

  • Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclo-sporin A. Am J Gastroenterol 1993;88:646–649.

    PubMed  CAS  Google Scholar 

  • Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 1994;39:374–380.

    PubMed  CAS  Google Scholar 

  • Feagan BG, McDonald JWD, Rochon J, et al, for the Canadian Crohn’s Relapse Prevention Trial Investigators. Low dose cyclosporin A for treatment of Crohn’s disease. N Engl J Med 1994;330:1846–1851.

    PubMed  CAS  Google Scholar 

  • Stange EF, Modigliani R, Pena AS, et al, and The European Study Group. European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. Gastroenterology 1995;109:774–782.

    PubMed  CAS  Google Scholar 

  • Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851–1856.

    PubMed  CAS  Google Scholar 

  • Kozorek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Int Med 1989;110:353–356.

    Google Scholar 

  • Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995;332:292–297.

    PubMed  CAS  Google Scholar 

  • Weinblatt BE. Methotrexate for chronic disease in adults. N Engl J Med 1995;332:330–331.

    PubMed  CAS  Google Scholar 

  • Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Int Med 1994;121:833–841.

    PubMed  CAS  Google Scholar 

  • Sartor RB. Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis, and experimental intestinal inflammation. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins; 1995:96–124.

    Google Scholar 

  • Ursung B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden. Gastroenterology 1982;83:550–562.

    Google Scholar 

  • Prantera C, Kohn A, Mangiarotti R, et al. Anti-mycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513–518.

    PubMed  CAS  Google Scholar 

  • Hampson SJ, Parker MC, Saverymuttu SH, et al. Results of quadruple antimycobacterial chemotherapy in 17 Crohn’s disease patients completing six months of treatment. Gastroenterology 1988;94:A170.

    Google Scholar 

  • Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn’s disease. Gut 1994;35:363–368.

    PubMed  CAS  Google Scholar 

  • Peppercorn MA. Are antibiotics useful in management of nontoxic severe ulcerative colitis? J Clin Gastroenterol 1993;17:14–17.

    PubMed  CAS  Google Scholar 

  • Chapman RW, Selby WS, Jewel DP. Controlled trial of metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210–1212.

    PubMed  CAS  Google Scholar 

  • Sandborn WJ. Pouchitis following ileal pouch-anal anastamosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107:1856–1860.

    PubMed  CAS  Google Scholar 

  • Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071–1075.

    PubMed  CAS  Google Scholar 

  • Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982;83:383–387.

    PubMed  CAS  Google Scholar 

  • Rutgeerts P, Hick M, Peeters M, et al. Prevention of clinical recurrence after ileal resection for Crohn’s disease with metronidazole: a placebo controlled study. Gastroenterology 1994;106:A764.

    Google Scholar 

  • Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn’s ileitis? J Clin Gastroenterol 1993;17:235–237.

    PubMed  CAS  Google Scholar 

  • Turunen U, Farkkila V, Hakala K, et al. A double-blind, placebo controlled six-month ciprofloxacin treatment improved prognosis in ulcerative colitis. Gastroenterology 1994;106:A786.

    Google Scholar 

  • Turunen U, Farkkila V, Valtonen V, et al. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease. Gastroenterology 1993;104:A793.

    Google Scholar 

  • Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992; 116:609–614.

    PubMed  CAS  Google Scholar 

  • Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33:922–928.

    PubMed  CAS  Google Scholar 

  • Breuer RI, Buto SK, Christ MI, et al. Rectal irrigation with short chain fatty acids for distal ulcerative colitis. Preliminary Report. Dig Dis Sci 1991;36:185–187.

    PubMed  CAS  Google Scholar 

  • Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994;89:179–184.

    PubMed  CAS  Google Scholar 

  • Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51–56.

    PubMed  CAS  Google Scholar 

  • Hanauer SB, Schulman M. Novel therapies for inflammatory bowel disease. Gastro Clin North Amer 1995;24:523–540.

    CAS  Google Scholar 

  • O’Donnell LJ, Arvind AS, Hoang P, et al. Doubleblind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut 1992;33:947–949.

    PubMed  Google Scholar 

  • Bjorck D, Dahlstrom A, Johansson L, et al. Treatment of the mucosa with local anesthetic in ulcerative colitis. Agents Actions Special Conference Issue, C60, 1992.

    Google Scholar 

  • Lechin F, van der Dijs B, Insausti CL, et al. Treatment of ulcerative colitis with clonidine. J Clin Pharmacol 1985;25:219–226.

    PubMed  CAS  Google Scholar 

  • Hanauer SB. Nicotine for colitis. The smoke has not yet cleared. N Engl J Med 1994;330:856–857.

    PubMed  CAS  Google Scholar 

  • Cottone M, Roselli M, Orlando A, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology 1994;106:643–648.

    PubMed  CAS  Google Scholar 

  • Pullan RD, Rhodes J, Ganesh S. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811–815.

    PubMed  CAS  Google Scholar 

  • Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332(15):988–992.

    PubMed  CAS  Google Scholar 

  • Lavy A, Wwisz G, Adir Y, et al. Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterol 1994;19:202–205.

    PubMed  CAS  Google Scholar 

  • Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220–223.

    PubMed  CAS  Google Scholar 

  • Bicks RC, Groshart KW, Chandler RW. The treatment of severe chronically active Crohn’s disease by T8 (suppressor cell) lymphaphersis. Gastroenterology 1985;88:A1325.

    Google Scholar 

  • van Dulleman HM, van Derventer SJH, Hommes DW, et al. Treatment of Crohn’s disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129–135.

    Google Scholar 

  • Stronkhorst A, Radema S, ten Berge I, et al. Phase I multiple-dose pilot study of chimeric monoclonal M-T412 (anti-CD-4) antibodies is Crohn’s disease. Gastroenterology 1993;104:A784.

    Google Scholar 

  • Jarnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994;35:1155–1158.

    PubMed  CAS  Google Scholar 

  • Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005–1013.

    PubMed  CAS  Google Scholar 

  • Present DH. Toxic megacolon. Med Clin North Am 1993;77:1129–1148.

    PubMed  CAS  Google Scholar 

  • Actis GC, Ottobrelli A, Pera A, et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993;17:10–13.

    PubMed  CAS  Google Scholar 

  • Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20–22.

    CAS  Google Scholar 

  • Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35:360–362.

    PubMed  CAS  Google Scholar 

  • Stemberg EM, Chrousos GP, Wilder RL, et al. The stress response and the regulation of inflammatory disease. Ann Int Med 1992;117:854–866.

    Google Scholar 

  • Nugent FW, Roy MA. Duodenal Crohn’s disease: an analysis of 89 cases. Am J Gastroenterol 1989;84:249–254.

    PubMed  CAS  Google Scholar 

  • Valori RM, Cockel R. Omeprazole for duodenal ulceration in Crohn’s disease. Br Med J 1990;300:438–439.

    CAS  Google Scholar 

  • Tan WC, Allan RN. Diffuse jejunoileitis of Crohn’s disease. Gut 1993;34:1374–1378.

    PubMed  CAS  Google Scholar 

  • Lewis JD, Fisher RL. Nutrition support in inflammatory bowel disease. Med Clin North Am 1994;78:1443–1456.

    PubMed  CAS  Google Scholar 

  • Ogorek CP, Fisher RS. Differentiation between Crohn’s disease and ulcerative colitis. Med Clin North Am 1994;78:1249–1258.

    PubMed  CAS  Google Scholar 

  • Rutgeerts P, Ggeboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:956–963.

    PubMed  CAS  Google Scholar 

  • Caprilli R, Castro M, Cirillo LC, et al. Postoperative recurrence in Crohn’s disease: definition, prediction and monitoring. Gastroenterol Int 1993;6:145–148.

    Google Scholar 

  • Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Gastroenterology 1994;108:345–349.

    Google Scholar 

  • Yu Q, Colot HV, Kyriacou CP, Hall JC (1987) Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology 109:404–413.

    Google Scholar 

Download references

Authors
  1. Richard H. ffrench-Constant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard T. Roush
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Flerida A. Cariño
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Entomology, Molecular Biology and Physiology Section, Black Mountain, Canberra ACT, Australia

    John Oakeshott  & Max J. Whitten  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag, New York

About this chapter

Cite this chapter

ffrench-Constant, R.H., Roush, R.T., Cariño, F.A. (1993). Drosophila as a Tool for Investigating the Molecular Genetics of Insecticide Resistance. In: Oakeshott, J., Whitten, M.J. (eds) Molecular Approaches to Fundamental and Applied Entomology. Springer Series in Experimental Entomology. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9217-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-9217-0_1

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4613-9219-4

  • Online ISBN: 978-1-4613-9217-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation